Oncology
Sven Schaffer and Nicole Raleigh interview at ESMO

ESMO 2024 - Sven Schaffer

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.

News

Views & Analysis

Oncology
Sven Schaffer and Nicole Raleigh interview at ESMO

ESMO 2024 - Sven Schaffer

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.

Deep Dive

Oncology
hexagon graphic

Heard on the pipeline: ASCO 2024

pharmaphorum's Jonah Comstock polls ASCO 2024 attendees on their best advice for oncology newcomers, capturing insights on scientific prowess, collaborative spirit, and navigating cutting-edge clinical trials.

Newsletters and Deep Dive
digital magazine

Webinars

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Oncology
Print
Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Podcasts

Video

Oncology
Sven Schaffer and Nicole Raleigh interview at ESMO

ESMO 2024 - Sven Schaffer

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.

Oncology
Video interview with Matteo Levisetti

ASCO 2024 - Matteo Levisetti

ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.

Oncology
ASCO 2024 - Chris Haqq interview with Jonah Comstock

ASCO 2024 - Chris Haqq

ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p

White Papers

Debates & Insight

Partner Content

Oncology
8th Tumor Models San Francisco Summit 2024
Partner Content

8th Tumor Models San Francisco Summit 2024

Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the fie